200 related articles for article (PubMed ID: 37873645)
1. The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders.
Li P; Li B; Yang N; Xu T; Zheng Z
Expert Opin Ther Pat; 2023; 33(7-8):477-492. PubMed ID: 37873645
[TBL] [Abstract][Full Text] [Related]
2. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the development of EGFR degraders: PROTACs and LYTACs.
Hong D; Zhou B; Zhang B; Ren H; Zhu L; Zheng G; Ge M; Ge J
Eur J Med Chem; 2022 Sep; 239():114533. PubMed ID: 35728507
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands.
Zhao HY; Wang HP; Mao YZ; Zhang H; Xin M; Xi XX; Lei H; Mao S; Li DH; Zhang SQ
J Med Chem; 2022 Mar; 65(6):4709-4726. PubMed ID: 35254067
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686.
Li Q; Guo Q; Wang S; Wan S; Li Z; Zhang J; Wu X
Eur J Med Chem; 2022 Aug; 238():114455. PubMed ID: 35594654
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
Shi S; Du Y; Huang L; Cui J; Niu J; Xu Y; Zhu Q
Bioorg Chem; 2022 Mar; 120():105605. PubMed ID: 35081479
[TBL] [Abstract][Full Text] [Related]
7. Targeting EGFR degradation by autophagosome degraders.
Zhu Z; Li J; Shen S; Al-Furas H; Li S; Tong Y; Li Y; Zeng Y; Feng Q; Chen K; Ma N; Zhou F; Zhang Z; Li Z; Pang J; Ding K; Xu F
Eur J Med Chem; 2024 Apr; 270():116345. PubMed ID: 38564826
[TBL] [Abstract][Full Text] [Related]
8. Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia - a patent review.
Vicente ATS; Salvador JAR
Expert Opin Ther Pat; 2023; 33(6):397-420. PubMed ID: 37494069
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC).
Zhang H; Zhao HY; Xi XX; Liu YJ; Xin M; Mao S; Zhang JJ; Lu AX; Zhang SQ
Eur J Med Chem; 2020 Mar; 189():112061. PubMed ID: 31951960
[TBL] [Abstract][Full Text] [Related]
10. Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide.
He K; Zhang Z; Wang W; Zheng X; Wang X; Zhang X
Bioorg Med Chem Lett; 2020 Jun; 30(12):127167. PubMed ID: 32317208
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab-based PROteolysis targeting chimera for effectual downregulation of NSCLC with varied EGFR mutations.
Vartak R; Deore B; Sanhueza CA; Patel K
Int J Biol Macromol; 2023 Dec; 252():126413. PubMed ID: 37598823
[TBL] [Abstract][Full Text] [Related]
12. Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020-2023).
Hajjo R; Sabbah DA; Bardaweel SK; Zhong HA
Expert Opin Ther Pat; 2024; 34(1-2):51-69. PubMed ID: 38450537
[TBL] [Abstract][Full Text] [Related]
13. Discovery of highly potent and selective CRBN-recruiting EGFR
Zhang W; Li P; Sun S; Jia C; Yang N; Zhuang X; Zheng Z; Li S
Eur J Med Chem; 2022 Aug; 238():114509. PubMed ID: 35691176
[TBL] [Abstract][Full Text] [Related]
14. Proteolysis targeting chimeras in non-small cell lung cancer.
Hagopian G; Grant C; Nagasaka M
Cancer Treat Rev; 2023 Jun; 117():102561. PubMed ID: 37178629
[TBL] [Abstract][Full Text] [Related]
15. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
[TBL] [Abstract][Full Text] [Related]
16. BET inhibitors: an updated patent review (2018-2021).
Chen H; Liu Z; Zheng L; Wang R; Shi L
Expert Opin Ther Pat; 2022 Sep; 32(9):953-968. PubMed ID: 35982031
[TBL] [Abstract][Full Text] [Related]
17. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
[TBL] [Abstract][Full Text] [Related]
18. Targeting androgen receptor degradation with PROTACs from bench to bedside.
Jia X; Han X
Biomed Pharmacother; 2023 Feb; 158():114112. PubMed ID: 36508999
[TBL] [Abstract][Full Text] [Related]
19. Targeting Epidermal Growth Factor Receptor in Non-Small-Cell-Lung Cancer: Current State and Future Perspective.
Bao SM; Hu QH; Yang WT; Wang Y; Tong YP; Bao WD
Anticancer Agents Med Chem; 2019; 19(8):984-991. PubMed ID: 30868964
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present).
Sun X; Xu S; Yang Z; Zheng P; Zhu W
Expert Opin Ther Pat; 2021 Mar; 31(3):223-238. PubMed ID: 33315482
[No Abstract] [Full Text] [Related]
[Next] [New Search]
